Neuronetics stock reports 9.1 percent revenue growth in Q2

Published on 09/24/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock generated USD 41.6 million in Q2 2026, up 9.1 percent year over year. Greenbrook revenue climbed 16.8 percent to USD 26.9 million.

Neuronetics stock, healthcare, medical devices, Q2 2026 revenue, analyst coverage, Nasdaq, Illustration mit AI erstellt.

Neuronetics stock (ISIN US64131A1051) closed at USD 2.88 on Nasdaq on September 23, 2026, down 1.03 percent from USD 2.91 and 16.3 percent below its 52-week high of USD 3.44. The medical device company reported Q2 2026 revenue of USD 41.6 million, up 9.1 percent from USD 38.1 million a year earlier.

Revenue growth comes from Greenbrook

According to Investing.com, Greenbrook clinic revenue rose 16.8 percent to USD 26.9 million in Q2 2026, while NeuroStar revenue declined 2.7 percent to USD 14.7 million. The comparison matters because the acquired clinic network supplied the growth, while the companys core therapy business contracted.

The same Q2 report showed an adjusted loss of USD 0.05 per share, narrower than the USD 0.12 consensus loss. Adjusted EBITDA reached USD 0.3 million, compared with a consensus loss of USD 3.7 million, while gross margin expanded to 61.1 percent from 46.6 percent in the prior-year quarter.

Analyst target stands above market price

On September 11, 2026, B.Riley initiated coverage with a Buy rating and a USD 5.00 price target, according to Investing.com. That target is USD 2.12 above the September 23 closing price, making the analysts valuation view materially different from the market quotation.

The companys investor-relations page lists the Q2 2026 results release dated August 11, 2026, alongside a corporate presentation dated August 11, 2026, according to Neuronetics. For investors, the central test is whether Greenbrooks 16.8 percent growth can offset the 2.7 percent decline in NeuroStar revenue.

Stock remains below yearly high

Neuronetics had a market capitalization of USD 200,412,864 as of September 23, 2026. Its 52-week range was USD 0.80 to USD 3.44, placing the latest close closer to the yearly high than to the low, but still 16.3 percent below the upper boundary.

Neuronetics stock closed at USD 2.88 on Nasdaq on September 23, 2026. The next market reference is the balance between clinic-led growth, core therapy revenue and the companys improved adjusted EBITDA profile.